Pegaspargase is a chemotherapy drug containing the active constituent pegaspargase. It is used to treat a type of blood cancer called Acute Lymphoblastic Leukemia (ALL).  This is a white blood cell cancer in which the immature white cells start growing out of control, thus preventing the production of functional blood cells. Combined with other chemotherapy drugs, this medication can help increase the chances of remission and long-term survival for people with ALL. 

Pegaspargase received its initial FDA approval in 1994 for treating leukemia. Since then, it has also been approved for use in various other countries. This medication is a prescription medication and should only be used under the supervision of a healthcare provider. It is particularly effective in treating children with ALL, who have a higher rate of remission and overall survival when included in their treatment plan.

Pegaspargase is an antineoplastic agent used to treat certain types of cancer, particularly acute lymphoblastic leukemia (ALL) and Non- Hodgkin's lymphoma.

Pegaspargase is an enzyme that breaks down the amino acid asparagine in the body. Cancer cells require asparagine to grow and divide and cannot produce their asparagine. By breaking down asparagine in the body, this medication can effectively "starve" cancer cells of this essential nutrient, slowing their growth and promoting cancer cell death. However, normal cells in the body can produce their asparagine and are not as affected by the enzyme as cancer cells. Therefore, this medicine selectively targets cancer cells while sparing healthy cells in the body to some extent.

Some of the more common side effects of pegaspargase include nausea, vomiting, loss of appetite, fatigue, headache, fever, chills, mouth sores, muscle or joint pain, skin rash or itching, and changes in blood clotting. However, this medication can also cause more serious side effects that require immediate medical attention. These include allergic reactions, liver damage, pancreatitis, blood clots, and high blood sugar.

Pegaspargase can cause severe allergic reactions, which can be life-threatening. It can cause inflammation of the pancreas, a condition known as pancreatitis. Symptoms of pancreatitis include severe abdominal pain, nausea, and vomiting. This medication can cause blood clotting, which increases the risk of stroke or heart attack. Sometimes the medication can cause kidney damage and affect the central nervous system, causing symptoms such as confusion, seizures, or difficulty concentrating. The immune system becomes weak with the long-term continuation of treatment which may increase the risk of infection.

Several precautions should be taken when using Pegaspargase. First, this medication should not be used in patients who are allergic to it or its components. Patients with pre-existing nerve damage or other conditions that affect nerve function may be at increased risk for nerve damage, and caution should be taken when using this medication in these patients. Patients with pre-existing heart conditions and kidney disease should be closely monitored during treatment. You should avoid contact with people with contagious illnesses and promptly report any signs of infection to your healthcare provider. Patients should be carefully monitored for signs of infection, bleeding, or anemia. Adjustments to the treatment regimen may be necessary to manage side effects and ensure the best possible outcomes.

Several precautions should be taken when using Pegaspargase. First, this medication should not be used in patients who are allergic to it or its components. Patients with pre-existing nerve damage or other conditions that affect nerve function may be at increased risk for nerve damage, and caution should be taken when using this medication in these patients. Patients with pre-existing heart conditions and kidney disease should be closely monitored during treatment. You should avoid contact with people with contagious illnesses and promptly report any signs of infection to your healthcare provider. Patients should be carefully monitored for signs of infection, bleeding, or anemia. Adjustments to the treatment regimen may be necessary to manage side effects and ensure the best possible outcomes.

1. KD Tripathi, Essentials of Medical Pharmacology, Anticancer drugs, 7th edition, 2013, 868
2. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Cytotoxic agents, 12th edition, 2011, 1720
3. Les Laboratories Servier, Electronic medicines compendium (EMC), [ Revised on Nov 2021] [ Accessed on 25th April 2023], https://www.medicines.org.uk/emc/files/pil.10824.pdf
4. Sigma-Tau Pharmaceuticals, US Food, and Drug Administration, [ Revised on March 2011] [ Accessed on 25th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103411s5126lbl.pdf

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.